NovaBridge has cash through 2028 as cancer and eye drug trials advance
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
NovaBridge reportedly has sufficient funds to last through 2028 as it moves forward with clinical trials for cancer and eye drugs. The company's progress may lead to a significant re-evaluation of its prospects. Additionally, a biopharma industry veteran has joined NovaBridge as the company approaches pivotal studies.